

« ... », ... (... - ...), ... , 5/7.

THE STATE OF PROTOXIDANT-ANTIOXIDANT SYSTEM OF THE BLOOD AND MUSCULAR TISSUE OF RATS AT EXPERIMENTAL REPERFUSION SYNDROME

O.A. Malchenko, L.V. Anisimova, M. I. Fedosov, A.V. Kubyshkin

SUMMARY

The experimental research performed on male Wistar rats has revealed that the development of experimental reperfusion syndrome is accompanied by changes in the protooxidant-antioxidant system and is characterized by progressive growth of the secondary active products of lipid peroxidation both in the blood serum and in the homogenates of previously ischemic skeletal muscles. At the same time the activity of the antioxidant enzymes grows in the blood serum, but decreases in the homogenates. Thereby the developing systemic imbalance of protooxidant-antioxidant system of the blood serum may have the key role in the pathology's progress and can lead to development of systemic complications, which later manifested formation the multiple organ dysfunction syndrome.

... « » ... [1, 6]. [3, 5].

59
180-210

[7]; ()
« » [8];
()
6
2-3 [4].
6
6, 12, 24 48 (M),
(m),
t-
<0,05.
“Biomat 5» ()
(-) 6
Fe³⁺.
[2];
() (. 1.).
1

	(/)	(/ x)	(/ b)	(/)
	M±m			
(n=11)	2,86 ± 0,32	18,21 ± 2,17	52,15 ± 5,94	25,05 ± 1,83
6 (n=10)	2,86 ± 0,34	23,72 ± 11,5 *	17,29 ± 3,6 ***	24,12 ± 1,40
6 (n=9)	4,72 ± 0,64 **	4,85 ± 1,09 ***	30,87 ± 1,56 ***	26,02 ± 1,82
12 (n=10)	4,63 ± 0,41 ***	8,73 ± 1,39 ***	35,52 ± 2,76 ***	28,86 ± 2,54
24 (n=8)	4,31 ± 0,95	4,27 ± 0,89 *** ### ,	34,25 ± 9,09	26,47 ± 3,21
48 (n=11)	4,79 ± 0,80 *	6,66 ± 0,71 ***	34,09 ± 5,34 *	20,4 ± 0,4 **

: *p<0,05, **p<0,01, ***p<0,001,

30% (p<0,01).

3 (p<0,001).

6 (.2),

40% (p<0,001).

2

/

	(/)	(/ x)	(/ b)	(/)
	M±m			
(n=11)	31,04 ± 1,12	0,38 ± 0,05	0,79 ± 0,05	208,33±8,97
6 (n=10)	67,68 ± 2,06 ***	0,31 ± 0,03	0,73 ± 0,07	291,2 ± 6,04 ***
6 (n=9)	65,16 ± 5,26 ***	0,63 ± 0,09 **	0,84 ± 0,14	294,39±12,32 ***
12 (n=10)	71,45 ± 4,18 ***	0,63 ± 0,07 **	0,40 ± 0,12 *	295,84±11,86 ***
24 (n=8)	80,12 ± 5,29 ***	0,90 ± 0,20 ***	0,36 ± 0,07 **	329,25±20,35 ***
48 (n=11)	86,82 ± 3,22 ***	0,89 ± 0,12 ***	0,20 ± 0,02 ***	428,19±13,97 ***

: *p<0,05, **p<0,01, ***p<0,001,

6 24 51%

65% (p<0,01)

73,4% (p<0,001).

41% (p<0,01).

6 76% (p<0,001), 34%.

110% (p<0,001), 2,5 (p<0,001)

41% (p<0,001).

62,5% (p<0,01), 58% (p<0,001), 137% (p<0,01), 54% (p<0,01)

12 62% (p<0,001).

(p<0,001), 52% 48-

32 % (p<0,01).

130% (p<0,001) 42% (p<0,001). 68% (p<0,05), 180%

(p<0,001) 64% (p<0,001). (p<0,01). 18%

49 % (p<0,05). % (p<0,001), 35% (p<0,05). 63,4

(p<0,001),
134% (p<0,001).

2

48

74% (p<0,001).

1.

/ . . . , . . . , . . .
[. . .]//
. - 2013.- 6, 1.- .33-38

2.

/ . . . , . . . //
. - 1983.- 3.- .33-36

3.

/ . . . , . . . //
. - 2010.- 12.- .70-76.

4.

/ . . . , . . . //
. - 1983.-
10.- .30-33

5.

/ . . . , . . . //
. - 2009.- .7, 1.- .37-60.

6.

/ . . . , . . . , . . . //
. - 2006.- 1.- .133-143.

7.

/ . . . , . . . [. . .]//
. - 1988.- 1.- .16-19.

8.

/ . . . , . . . //
. - 1971.- 10.- .89-91

9.

/ . . . , . . . [. . .]//
. - 2013.- 4., 26.- .33-37.

1.

2.

6

10.

/ . . . // .-2013.- 1.- .29-31.

48

24-48

3.

11. NOX2 protects against progressive lung injury and multiple organ dysfunction syndrome/L.C. Whitmore , K.L. Goss , E.A. Newell [et all] /Am J Physiol Lung Cell Mol Physiol. -2014 Vol.307, 1.- .71-82.

12. van Griensven M. Cytokines as biomarkers in polytraumatized patients / . van Griensven // Unfallchirurg.- 2014 117.- .699-702.